

You Can Make New FSGS Treatments Possible

CLINICAL TRIALS FOR FSGS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (ENROLLMENT COMPLETE) (Travere)	FSGS	8–75	Sparsentan	≥ 30
THE TRACTION-2 STUDY (Goldfinch Bio)	FSGS, treatment-resistant MCD, Diabetic Nephropathy	18–75	GFB-887	≥ 45
THE PODO TRIAL (Pfizer)	FSGS	18+	PF-06730512	≥ 30
ACTHAR FOR TREATMENT OF POST-TRANSPLANT FSGS (COMING SOON) (Mallinckrodt)	Recurrent FSGS	18+	Acthar	UPCR > 1 gram/day
STUDY OF VX-147 IN ADULTS WITH APOL1-MEDIATED FSGS (Vertex)	APOL1-Mediated FSGS	18–65	VX-147	≥ 30
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (COMING SOON) (Boehringer Ingelheim)	FSGS, IgAN, MN	18+	BI 685509	≥ 20 & < 90
AFFINITY (Chinook)	FSGS, IgAN, Alport Syndrome, DKD, Diabetic Nephropathy	18+	Atrasentan	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0–75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
ACTION (AUSTRALIA - ACTIVE, NOT RECRUITING) (Dimerix)	FSGS	18–80	Propagermanium	≥ 25
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New MCD Treatments Possible

CLINICAL TRIALS FOR MCD PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE TRACTION-2 STUDY (Goldfinch Bio)	Treatment-resistant MCD, FSGS, Diabetic Nephropathy	18–75	GFB-887	≥ 45
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New IgAN Treatments Possible

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PROTECT (Travere)	IgAN	18+	Sparsentan	≥ 30
SPARTAN (LEICESTER) (Travere)	IgAN	18+	Sparsentan	≥ 30
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (COMING SOON) (Boehringer Ingelheim)	IgAN, FSGS, MN	18+	BI 685509	≥ 20 & < 90
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	IgAN, MN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
AFFINITY (Chinook)	IgAN, FSGS, Alport Syndrome, DKD, Diabetic Nephropathy	18+	Atrasentan	≥ 30
ALIGN (Chinook)	IgAN	18+	Atrasentan	≥ 30
SAFETY & TOLERABILITY OF BION-1301 IN HEALTHY VOLUNTEERS & ADULTS WITH IGAN (CALIFORNIA, EL PASO TEXAS, LONDON) (Chinook)	IgAN	18+	BION-1301	> 45
THE ARTEMIS-IGAN STUDY (Omeros)	IgAN	18+	OMS721	≥ 30
STUDY OF CEMDISIRAN IN ADULTS WITH IGAN (Alnylam)	IgAN	18–65	Cemdisiran	≥ 30
NEFIGARD (Calliditas)	IgAN	18+	Nefecon	≥ 45
STUDY OF RAVULIZUMAB IN IGAN & PROLIFERATIVE LUPUS NEPHRITIS (Alexion)	IgAN, Lupus Nephritis	18-75	Ravulizumab	≥ 30
SAFETY & EFFICACY OF LNP023 IN ADULTS WITH KIDNEY DISEASE CAUSED BY INFLAMMATION (ACTIVE, NOT RECRUITING) (Novartis)	IgAN	18+	LNP023	≥ 30
SAFETY & EFFICACY OF VIS649 FOR IGAN (Visterra)	IgAN	18+	VIS649	≥ 45
EFFECTIVENESS & SAFETY OF IONIS-FB-LRX IN IGAN (AUSTRALIA, CANADA, NEW ZEALAND) (Ionis)	IgAN	18–75	IONIS-FB-LRx	> 40
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

See next page for more Transplant and CKD Trials.

You Can Make New IgAN Treatments Possible

CLINICAL TRIALS FOR IGAN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New Membranous Nephropathy Treatments Possible

CLINICAL TRIALS FOR MEMBRANOUS PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
STUDY TO TEST EFFECT OF DIFFERENT DOSES OF BI 685509 ON KIDNEY FUNCTION IN CKD WITHOUT DIABETES (COMING SOON) (Boehringer Ingelheim)	MN, FSGS, IgAN	18+	BI 685509	≥ 20 & < 90
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	MN, IgAN, C3G, Dense Deposit Disease, or Lupus Nephritis	18+	APL-2	≥ 30
M-PLACE (MorphoSys)	MN	18-80	MOR202	≥ 30
NEW-PLACE (MorphoSys)	MN	18-80	MOR202	≥ 30
REBOOT (GlaxoSmithKline)	MN	18-75	Belimumab, Rituximab	≥ 40
EFFICACY & SAFETY OF LNP023 COMPARED WITH RITUXIMAB IN ADULTS WITH IDIOPATHIC MN (Novartis)	MN	18+	LNP023	≥ 45
EFFICACY & SAFETY OF OBINUTUZUMAB IN PARTICIPANTS WITH PRIMARY MN (COMING SOON) (Hoffmann-La Roche)	MN	18-75	Obinutuzumab	≥ 40
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New C3G Treatments Possible

CLINICAL TRIALS FOR C3G PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE DISCOVERY TRIAL (ACTIVE, NOT RECRUITING) (Apellis)	C3G, Dense Deposit Disease, IgAN, MN, or Lupus Nephritis	18+	APL-2	≥ 30
THE NOBLE STUDY (Apellis)	C3G or IC-MPGN that has recurred after kidney transplant	18+	Pegcetacoplan	≥ 30
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3G, C3GN, or IC-MPGN	17–65	Ach-0144471	≤ 75
EFFICACY & SAFETY OF LNP023 IN C3G PATIENTS TRANSPLANTED & NOT TRANSPLANTED (ACTIVE, NOT RECRUITING) (Novartis)	C3G	18–65	LNP023	≥ 30
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New C3GN Treatments Possible

CLINICAL TRIALS FOR C3GN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3GN, C3G, or IC-MPGN	17-65	Ach-0144471	≤ 75
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New MPGN Treatments Possible

CLINICAL TRIALS FOR MPGN PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
THE NOBLE STUDY (Apellis)	IC-MPGN that has recurred after kidney transplant or C3G	18+	Pegcetacoplan	≥ 30
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	IC-MPGN, C3G, or C3GN	17-65	Ach-0144471	≤ 75
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18-75	Extracorporeal photopheresis	N/A
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your
part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at [NephCure.org/TrialTable](https://www.NephCure.org/TrialTable)

You Can Make New Treatments Possible

CLINICAL TRIALS FOR TRANSPLANT PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
PHOTOPHERESIS IN THE PREVENTION OF ACUTE KIDNEY REJECTION IN HIGHLY SENSITIZED DE NOVO TRANSPLANT RECIPIENTS (SPAIN - COMING SOON) (Mallinckrodt)	De novo transplant	18–75	Extracorporeal photopheresis	N/A
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0–75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
TREG MODULATION WITH CD28 & IL-6 RECEPTOR ANTAGONISTS (Bristol-Myers Squibb)	De novo living donor transplant	18-70	CD28 & IL-6 Receptor Antagonists	N/A
FREEDOM-1 (Talaris)	De novo living donor transplant	18+	FCR001	N/A
PILOT STUDY USING AUTOLOGOUS REGULATORY T CELL INFUSION ZORTRESS IN TRANSPLANT RECIPIENTS (Novartis)	ESRD & de novo transplant	18-65	Apheresis	N/A
CIRRUS I STUDY (Novartis)	De novo transplant	18+	CFZ533	N/A
EMPATHY (ITALY - COMING SOON) (Boehringer Ingelheim)	Obesity & CKD	18+	Empagliflozin	> 60

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable

You Can Make New Treatments Possible

CLINICAL TRIALS FOR PEDIATRIC PATIENTS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (ENROLLMENT COMPLETE) (Travere)	FSGS	8–75	Sparsentan	≥ 30
POST-APPROVAL STUDY OF LIPOSORBER LA-15 SYSTEM FOR PEDIATRIC & DRUG RESISTANT ADULT PATIENTS WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	0–75	Liposorber LA-15 System	≥ 60 or post-transplant recurrence
ACCOLADE (ChemoCentryx)	C3G (DDD or C3GN)	12+	Avacopan	N/A
ACH-0144471 FOR C3G, C3GN, & IMMUNE COMPLEX MPGN (ACTIVE, NOT RECRUITING) (Alexion)	C3G, C3GN, or IC-MPGN	17–65	Ach-0144471	≤ 75

Visit [KidneyHealthGateway.com](https://www.kidneyhealthgateway.com) to play your part in cutting-edge kidney research.

This is a living document and was last updated on 4/30/21.



NEPHCURE®
Kidney International

Trial Table updated monthly at NephCure.org/TrialTable